Clinical Trial Update: A Study of Pertuzumab With High-Dose Trastuzumab for the Treatment of Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Breast Cancer (MBC) With Central Nervous System (CNS) Progression Post-Radiotherapy [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating pertuzumab with high-dose trastuzumab for HER2-positive metastatic breast cancer with CNS progression after radiotherapy; study complet…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Pertuzumab (pertuzumab)
• Trastuzumab (high-dose) (trastuzumab)

Snippet

Sponsor: Genentech, Inc. | Conditions: Metastatic Breast Cancer | Phase 2 | Status: COMPLETED | Results posted: 2020-03-27